Objective-8-Hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (ETC-1002) is a small molecule with a unique mechanism of action shown in nonclinical studies to modulate pathways of cholesterol, fatty acid, and carbohydrate metabolism. In previous phase 2 clinical trials, once daily oral treatment with ETC-1002 significantly reduced low-density lipoprotein-cholesterol in patients with hypercholesterolemia. In this trial, the lipid-lowering efficacy of ETC-1002 was evaluated in patients with type 2 diabetes mellitus and hypercholesterolemia. Additional cardiometabolic biomarkers, including glycemic measures, were also assessed. Approach and Results-A single-center, double-blind, placebo-controlled trial evaluated 60 patients with type 2 diabetes mellitus and elevated low-density lipoprotein-cholesterol. Patients discontinued all diabetes mellitus and lipid-regulating drugs and were randomized to receive ETC-1002 80 mg QD for 2 weeks followed by 120 mg QD for 2 weeks or placebo for 4 weeks. ETC-1002 lowered low-density lipoprotein-cholesterol levels by 43±2.6% (least squares mean±SE), compared with a reduction of 4±2.5% by placebo at day 29 (P<0.0001; primary end point). Non-high-density lipoproteincholesterol and total cholesterol were also significantly lowered by ETC-1002 compared with placebo (P<0.0001). Highsensitivity C-reactive protein was reduced by 41% (median) compared with a placebo reduction of 11% (P=0.0011). No clinically meaningful safety findings were observed.
P atients with type 2 diabetes mellitus (T2DM) are at higher risk for cardiovascular disease (CVD) [1] [2] [3] and many fail to achieve their low-density lipoprotein-cholesterol (LDL-C) goal on statin therapy. [4] [5] [6] The use of statins in patients with diabetes mellitus is supported by a large body of clinical data demonstrating reduced risk for CVD. However, recently published meta-analyses of clinical studies suggest an increased risk for worsening of glycemic control and new onset diabetes mellitus associated with statin use, which presents a challenge to effective LDL-C lowering for diabetics. [7] [8] [9] [10] [11] [12] In 2012, the Food and Drug Administration required that language be added to statin labels reporting increases in hemoglobin A1C and fasting serum glucose. 13 A therapy demonstrating substantial lowering of LDL-C with neutral to beneficial effects on glycemic control and additional CVD risk factors in patients with T2DM is not currently available.
See accompanying editorial on page 477
ETC-1002 (8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid) is currently in phase 2 clinical development to treat hypercholesterolemia, with early evidence for favorable effects on other cardiometabolic biomarkers, such as insulin sensitivity, inflammation, and high blood pressure. Nonclinical studies show that ETC-1002 modulates 2 distinct and complementary molecular targets regulating lipid homeostasis: hepatic ATP-citrate lyase and AMP-activated protein kinase (Figure 1 ). 14 Inhibition of ATP-citrate lyase by ETC-1002 rapidly reduces levels of acetyl-CoA, the final common substrate for both fatty acid and sterol synthesis, at a point in the lipid synthesis pathway upstream of 3-hydroxy-3-methylglutaryl-CoA reductase, the molecular target of statins. In addition, ETC-1002-mediated AMP-activated protein kinase activation reduces lipid synthesis, regulates carbohydrate metabolism, and reduces inflammation and adiposity in nonclinical studies. 14, 15 Thus, ETC-1002, via effects at multiple points, regulates hepatic lipid homeostasis and has favorable effects on glucose regulation in animal models. [15] [16] [17] [18] A previous phase 2 placebo-controlled trial in 177 patients with hypercholesterolemia (baseline LDL-C between 130 and 220 mg/dL), with or without elevated triglyceride levels, showed a dose-related, statistically significant lowering of LDL-C levels up to 27±2.2% (least squares mean±SE) after 12 weeks of treatment with ETC-1002 compared with a 2.1±2.2% decrease with placebo (P<0.0001). 19 The aim of this phase 2, placebo-controlled, double-blind, parallel group trial was to evaluate the lipid-altering effects of ETC-1002 in patients with both elevated LDL-C (≥100 mg/dL) and T2DM.
Materials and Methods
Materials and Methods are available in the online-only Supplement. No prior therapies indicated 0 2 (6.7)
Nonstandard Abbreviations and Acronyms
DBP indicates diastolic blood pressure; HbA1C, hemoglobin A1C; HDL-C, high-density lipoprotein-cholesterol; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein-cholesterol; and SBP, systolic blood pressure.
*n=30 except for LDL-C in which 1 patient from the ETC-1002 group had no baseline.
†Baseline is defined as the mean of the values from days −1 to 1. ‡Baseline is defined as the value from day 1. §Baseline is defined as the value from day −1. ║Blood pressure was measured in triplicate with the first measurement dropped and the mean of the second 2 calculated.
Results

Baseline, Demographic, and Disease Characteristics
Baseline and demographic characteristics were generally similar between the 2 groups. The mean body mass index (BMI) was slightly higher in the ETC-1002 group than in the placebo group (30.6 versus 29.2 kg/m 2 ), corresponding to a greater number of patients with BMI ≥30 kg/m 2 (19 versus 12; Table 1 ). Nearly all patients were receiving diabetes mellitus therapy (97%) before the trial, most commonly metformin monotherapy (95%). Hypertension was the most frequently reported additional medical condition, occurring in 8 patients in each group.
Mean baseline lipid parameters for fasting calculated LDL-C were similar between the 2 groups (ETC-1002, 125.2 mg/dL and placebo, 128.4 mg/dL). Median fasting triglyceride was higher in the ETC-1002 group than in the placebo group (181.5 versus 152.0 mg/dL; Table 1 ). The median high-sensitivity C-reactive protein levels were similar in the ETC-1002 and the placebo groups. Comparison of baseline glycemic parameters showed a lower mean fasting plasma glucose level in the ETC-1002 group compared with placebo (185.9 versus 198.1 mg/dL). The baseline mean values were similar between the 2 groups for the other fasting glycemic markers tested, including insulin, hemoglobin A1C, and fructosamine.
Primary and Other Efficacy End Points
Lipid End Points
Using prespecified ANCOVA models, significant reductions in LDL-C as well as several other fasting lipid parameters were observed after treatment with ETC-1002 compared with placebo (Tables 2 and 3; Figure 2A ). At day 29, LDL-C was reduced by 42.9% (least squares mean percentage change from baseline) for the ETC-1002 group compared with 4.0% for the placebo group. The difference in the reduction for the ETC-1002 group compared with placebo (the primary end point) was 39.0%, which was highly statistically significant (95% confidence interval [CI], −46.2, −31.7; P<0.0001). A similar analysis was performed at day 15, which assessed the effect of the 80 mg QD dosage. The magnitude of LDL-C All analyses were performed in the mITT population. CI indicates confidence interval; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; LS, least squares; and mITT, modified intent to treat.
*Baseline is defined as the mean of the values from days −1 to 1. †Missing values at day 29 were imputed using the last observation carried forward procedure (only postbaseline values were carried forward).
‡LS mean percentage change from baseline to day 29 based on ANCOVA model with effect of treatment and baseline value as a covariate. §One patient from the ETC-1002 group had no baseline LDL-C value (because of an error processing the sample with triglyceride >400 mg/ dL) and was excluded from the mITT population for that end point but was included in the mITT population for other efficacy end points.
lowering seemed to be dose related and the difference from placebo remained highly significant (difference, −26.6% [95% CI, −32.5, −20.7; P<0.0001]).
Reductions in LDL-C at day 29 occurred in all ETC-1002 patients across a broad range of individual baseline LDL-C and triglyceride values (Figure 3 ). Twenty-five of 29 patients (86%) treated with ETC-1002 had a 30% or greater reduction in LDL-C, whereas 9 patients (31%) had a 50% or greater reduction.
The ETC-1002-treated group also showed significant mean percentage reductions versus placebo at day 29 in non-high-density lipoprotein-cholesterol (difference, −31.4 [95% CI, −38.0, −24.8; P<0.0001]) and total cholesterol (difference, −24.6 [95% CI, −29.9, −19.4; P<0.0001]; Tables 2 and 3; Figure 2A ). Levels of triglyceride, highdensity lipoprotein-cholesterol, and free fatty acids did not change significantly with ETC-1002-treatment (Tables 2 and  3 ; Figure 2A ). ETC-1002 treatment reduced high-sensitivity C-reactive protein by 40.5% (median percentage reduction from baseline) compared with 11.0% with placebo at day 29 (P=0.0011; Figure 2B ).
Glycemic End Points
ETC-1002 treatment did not result in a worsening of glycemic control. A nonsignificant reduction of all prespecified glycemic markers was observed at day 29 with ETC-1002 treatment compared with placebo (Table 4) Post hoc analysis showed a significant reduction of daily peak glucose with ETC-1002 treatment compared with placebo (−24.4 mg/dL) between the hours of 6 am and 12 pm (with breakfast; 95% CI, −46.3, −2.5; P=0.0295). Nonsignificant trends were also observed in peak glucose between the hours of 12 pm to 6 pm (with lunch; difference, −15.6 mg/dL) and 6 pm to 12 am (with dinner; difference, −19.5 mg/dL).
Further post hoc analysis of the 5 measured glycemic end points in obese patients (BMI≥30 kg/m 2 ) showed a similar nonsignificant trend toward improvement with ETC-1002 treatment as was seen in the overall patient population ( Table  II in 
Blood Pressure
Most patients had well-controlled blood pressure at baseline, as uncontrolled blood pressure (systolic blood pressure, ≥150 mm Hg or diastolic blood pressure, ≥100 mm Hg) was an exclusion criteria. Overall 24-hour ambulatory blood pressure monitoring showed no differences between treatment groups in mean changes from baseline to day 28 (Table III in 
the online-only Data Supplement).
A post hoc analysis of a subgroup of patients with mild elevation in diastolic blood pressure at baseline (>80 mm Hg) showed that treatment with ETC-1002 (n=5) decreased diastolic blood pressure compared with placebo (n=4) on day 28 (difference, −7.3 mm Hg [95% CI, −14.6, −0.1; P=0.0474]). In a similar post hoc analysis of patients with mild elevation in systolic blood pressure at baseline (>120 mm Hg), treatment with ETC-1002 (n=13) trended toward a decrease in systolic blood pressure compared with placebo (n=17) on day 28 (difference, −2.4 mm Hg [95% CI, −7.3, 2.5; P=0.3271]).
Safety
ETC-1002 was generally safe and well tolerated in this trial. The number of adverse events reported and the percentage of patients with adverse events in the ETC-1002 group (45 events in 14 patients [47%]) were lower than those in the placebo group (52 events in 21 patients [70%]; Table 5 ). The most frequently reported adverse event was hyperglycemia, a potential consequence of discontinuation of diabetes mellitus medications before dosing, which occurred in almost twice the number of patients in the placebo group compared with the ETC-1002 group (10 versus 6 patients). Other adverse events, occurring more frequently in the ETC-1002-treated group compared with placebo, were headache (in 6 and 3 patients, respectively) and constipation (in 2 and no patients, respectively). Of note, no patient dosed with ETC-1002, or with placebo, reported myalgia. The majority of adverse events were mild in severity and all adverse events were resolved by the end of the trial. One patient in the placebo group discontinued because of myocardial infarction ( Table  I in 
the online-only Data Supplement).
Mean changes from baseline to day 29 in most clinical chemistry or hematology parameters were similar for the ETC-1002 and placebo groups, with the exception of the following changes with ETC-1002 treatment: mild to moderate mean increases in uric acid and homocysteine and mild decreases in alkaline phosphatase and hemoglobin (Table IV in the online-only Data Supplement). No clinical sequelae or interventions were associated with these laboratory findings. Evaluation of clinical chemistry laboratory parameters of particular interest to LDL-C-lowering drugs (alanine transaminase, aspartate aminotransferase, total bilirubin, creatinine, and creatine kinase) showed no clinically meaningful changes compared with baseline (Table IV in the online-only Data Supplement). Abnormal liver function tests of >3× the upper limit of normal or creatine kinase levels of >5× upper limit of normal were not observed in patients treated with ETC-1002.
Results for ECGs, vital signs, waist and ankle circumference, and physical examinations showed no dose-limiting, clinically meaningful trends. Interestingly, the mean decreases from baseline in weight and waist circumference were numerically greater in the ETC-1002 group than in the placebo group. The mean (SD) decrease of weight on day 29 was −1.4 kg (1.53) for the ETC-1002 group compared with −0.9 kg (1.07) decrease for the placebo group. A post hoc subgroup analysis showed that in obese patients (BMI≥30 kg/m 2 ), 10 of 19 (53%) of those treated with ETC-1002 had a 2-kg or greater reduction compared with 1 of 12 (8%) patients in the placebo group.
Discussion
This was a phase 2 proof-of-concept clinical trial designed to evaluate the lipid-lowering effects of ETC-1002 in hypercholesterolemic patients with T2DM. Significant LDL-C lowering after ETC-1002 120 mg treatment versus placebo was observed at day 29, the primary end point. The magnitude of LDL-C lowering with ETC-1002 treatment at day 29 was 43% compared with a 4% reduction for patients given placebo (P<0.0001). ETC-1002 treatment lowered LDL-C in all patients, the majority of whom (25 of the 29 patients) experienced a 30% or greater drop in LDL-C independent of baseline LDL-C. In addition, a significant LDL-C reduction was also observed with the lower dose, ETC-1002 80 mg, versus placebo at day 15. The reduction of LDL-C was accompanied by corresponding significant reductions in related lipid parameters including non-high-density lipoprotein-cholesterol and total cholesterol compared with placebo (P<0.0001). The inflammatory biomarker, high-sensitivity C-reactive protein, known to be associated with CVD risk, was also significantly reduced with ETC-1002 treatment compared with placebo (41% versus 11%; P=0.0011).
The reduction in LDL-C observed in patients with hypercholesterolemia and T2DM is greater than that observed in a previous placebo-controlled phase 2 trial in hypercholesterolemic patients (n=177) treated for 12 weeks in which ETC-1002 significantly lowered LDL-C by 27% in the 120 mg group compared with 2% in the placebo group. 19 It is Nausea 0 2 (7) *Common adverse events occurred in ≥5% of patients in ≥1 treatment group and are listed in decreasing frequency of the incidence of the adverse event for the total trial population.
unclear why the magnitude of LDL-C lowering in the current trial was substantially greater than that of the previous trial. In addition to population differences (diabetics versus nondiabetics), other factors that may have contributed to the differences include trial design (inpatient versus outpatient), baseline LDL-C (125 versus 165 mg/dL), and predominance of Hispanic patients in this trial (98%). The greater weight loss trend observed in this trial in patients treated with ETC-1002 may have been, in part, because of the greater number of obese patients in the ETC-1002 group (19 versus 12 in the placebo group, with a mean BMI of 30.6 versus 29.2 kg/m 2 , respectively) and the consequential weight loss because of a healthier lifestyle during the 35 days in the clinic. Future trials with larger numbers of T2DM patients who are not restricted to a clinic, longer treatment duration, and higher doses of ETC-1002 may provide insight to the effects of ETC-1002 on other relevant cardiometabolic measures, including glycemic control, blood pressure reduction, and weight loss.
Assessment of standard safety parameters indicated that ETC-1002 was generally safe and well tolerated in this population of hypercholesterolemic patients with T2DM. Treatment was not associated with dose-limiting adverse events and the majority of adverse events were mild in severity. No patients in the ETC-1002 group had an adverse event that led to withdrawal of trial drug.
Effective lowering of elevated LDL-C in patients with T2DM is a challenging unmet medical need. These patients are at an increased risk of CVD 1,2 and many are unable to achieve LDL-C treatment goals. 3 Furthermore, although statins are widely prescribed for the treatment of hypercholesterolemia in patients with T2DM, increases in hemoglobin A1C and fasting plasma glucose have been reported with statin therapy. 13 The results of this trial suggest that ETC-1002 may offer a potential novel therapeutic approach that is well tolerated and can significantly lower LDL-C and high-sensitivity C-reactive protein in patients with T2DM without worsening glycemic control. The potential beneficial effects of ETC-1002 on LDL-C and other cardiometabolic risk factors, including blood glucose, blood pressure, and body weight, support further clinical investigation in larger clinical trials.
